LOXO-305: Next-gen BTK inhibitor safe and effective in B-cell malignancies

ORLANDO – The antitumor activity of the novel drug was significant among patients with chronic lymphocytic leukemia and mantle cell lymphoma.

Read the full article here

Related Articles